Doha, 1 May 2025 – In a significant advancement for public health in Qatar, Ebn Sina Medical, a leading pharmaceutical supplier and subsidiary of Aamal Company Q.P.S.C., has expanded its strategic partnership with global healthcare leader Novo Nordisk to introduce Wegovy® (Semaglutide 2.4mg) – now officially available in Qatar.
This milestone underscores a shared commitment to tackling obesity, a major public health concern in the region, through evidence-based treatment and healthcare innovation.
Addressing Qatar’s Obesity Epidemic
Obesity is one of Qatar’s most pressing healthcare challenges.
- 41% of adults in Qatar are classified as obese (BMI ≥ 30 kg/m²), with 46% of women affected.
- Over 76% of the population is overweight or obese.
- These conditions are closely linked to high rates of type 2 diabetes, cardiovascular diseases, and other metabolic disorders.
About Wegovy® (Semaglutide 2.4mg)
Wegovy® is the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) approved for chronic weight management in adults and adolescents aged 12 and above.
This breakthrough weight loss medication works by reducing appetite and increasing the feeling of fullness, helping individuals manage their weight more effectively when combined with a reduced-calorie diet and increased physical activity.
Proven Clinical Benefits:
- Up to 17% mean weight loss over 2 years
- One-third of patients experience ≥20% body weight loss
- Significant improvement in waist circumference, blood pressure, lipid levels, and glycemic control
- 20% reduction in major adverse cardiovascular events (MACE) in adults with established CVD
- 80% regression from prediabetes to normoglycemia in clinical trials
Launch Event Highlights
The launch event was attended by:
- H.E. Mr. Anders Bjørn Hansen, Ambassador of Denmark to the UAE and Qatar
- Mr. Rashid Al Mansoori, CEO of Aamal Company
- Mr. Manvendra Singh, General Manager, Novo Nordisk Qatar
- Dr. Nayla Mansour, Commercial Director, Ebn Sina Medical
- Prof. Usama Al Alami, Head of Medical, Novo Nordisk Qatar
Leadership Statements
Mr. Rashid Al Mansoori, CEO of Aamal Company:
“This launch reinforces our mission to advance Qatar’s healthcare infrastructure and deliver innovative medical solutions in line with Qatar National Vision 2030.”
Mr. Manvendra Singh, GM of Novo Nordisk Qatar:
“We are proud to bring our legacy in chronic disease management to support obesity treatment in Qatar with science-backed therapies like Wegovy®.”
Mr. Essam Faragalla, GM of Ebn Sina Medical:
“Our partnership with Novo Nordisk reflects our dedication to patient-centric care and access to world-class healthcare solutions for the people of Qatar.”
Transforming Weight Management in Qatar
With its approval for both adults and adolescents, Wegovy® is expected to transform medical weight loss solutions in Qatar and support early intervention in young populations — especially as nearly 20% of adolescents in Qatar are now living with obesity.
This initiative supports the broader goals of the National Health Strategy 2018–2022 and Qatar Vision 2030 by promoting preventive care, early intervention, and sustainable healthcare development.
